Hepatitis C virus-related cryoglobulinemic vasculitis

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Hepatitis C virus (HCV) infection impacts 170 million globally, causing hepatitis and extra-hepatic manifestations.
• Chronic HCV (70% of cases) can lead to cirrhosis or hepatocellular carcinoma.
• Extra-hepatic manifestations like mixed cryoglobulinemia (MC) and non-Hodgkin lymphomas (NHL) affect 10% of HCV patients, with cryoglobulinemic vasculitis (CV) presenting diverse symptoms.

Purpose of the Study:

• To evaluate the efficacy of direct antiviral agents (DAAs) in treating Hepatitis C virus (HCV) infection, particularly in patients with cryoglobulinemic vasculitis (CV).
• To determine the impact of DAAs on both viral eradication and clinical manifestations of CV.
• To establish optimal treatment strategies for CV patients based on disease severity.

Main Methods:

• Review of studies on direct antiviral agents (DAAs) for HCV treatment.
• Analysis of HCV eradication rates across different genotypes.
• Assessment of clinical improvement in CV patients undergoing DAA therapy.

Main Results:

• DAAs achieve high HCV eradication rates (90-100%) irrespective of genotype.
• DAA treatment shows comparable efficacy in viral eradication for CV patients.
• Clinical improvement of vasculitis is observed in approximately 50% of CV patients treated with DAAs.

Conclusions:

• DAA therapy is recommended as a first-line treatment for mild to moderate CV disease.
• Severe vasculitis cases require DAA therapy combined with a second-line treatment, such as rituximab (RTX), potentially with apheresis.